SUPNSupernus Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−11% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −11% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SUPN is trading
Supernus Pharmaceuticals, Inc. is −7.3% over the past year while the S&P 500 is +18%: 26 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −11%
vs 200-day average · a clear downtrend
- RSI (14)
- 49
RSI (14) · neutral
- Below its 52-week high
- 25%
Below its 52-week high
Details›
- Last close2026-10-09
- $42.68
- 1 monthS&P 500 +2.7%
- +2.3%
- 1 yearS&P 500 +18%
- −7.3%
- 5 yearsS&P 500 +88%
- +58%
- vs 50-day average$44.46
- −4.0%
- 52-week high
- $57.00
- 52-week low
- $41.31
- Annualised volatility
- 36%
| Year | Return |
|---|---|
| 2026 (year to date) | −14% |
| 2025 | +37% |
| 2024 | +25% |
| 2023 | −19% |
| 2022 | +22% |
| 2021 | +16% |
| 2020 | +6.1% |
| 2019 | −29% |
| 2018 | −17% |
| 2017 | +58% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +5.3% |
| Feb | 10 | 4 of 10 | −2.8% |
| Mar | 10 | 5 of 10 | +3.2% |
| Apr | 10 | 6 of 10 | +2.6% |
| May | 10 | 3 of 10 | −0.79% |
| Jun | 10 | 5 of 10 | +2.2% |
| Jul | 11 | 7 of 11 | +1.2% |
| Aug | 11 | 6 of 11 | +2.6% |
| Sep | 11 | 4 of 11 | −1.1% |
| Oct | 11 | 6 of 11 | −0.81% |
| Nov | 10 | 6 of 10 | +1.1% |
| Dec | 10 | 6 of 10 | +2.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #21 of 41 by RyuScore